Evidence map›Paper›PMID 33452503›Full record

ArticleNature protocols2021

Facile synthesis of per(6-O-tert-butyldimethylsilyl)-α-, β-, and γ-cyclodextrin as protected intermediates for the functionalization of the secondary face of the macrocycles.

Gábor Benkovics, Milo Malanga, Giovanna Cutrone, Szabolcs Béni, Antonio Vargas-Berenguel, Juan Manuel Casas-Solvas

Abstract read
PubMed Publisher
In one paragraph

Article in Nature protocols, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Gábor BenkovicsCycloLab Ltd., Budapest, Hungary.
Milo MalangaCycloLab Ltd., Budapest, Hungary.
Giovanna CutroneDepartment of Chemistry and Physics, University of Almería, Almería, Spain.
Szabolcs BéniDepartment of Pharmacognosy, Semmelweis University, Budapest, Hungary.ORCID http://orcid.org/0000-0001-7056-6825
Antonio Vargas-BerenguelDepartment of Chemistry and Physics, University of Almería, Almería, Spain.
Juan Manuel Casas-SolvasDepartment of Chemistry and Physics, University of Almería, Almería, Spain. jmcasas@ual.es.ORCID http://orcid.org/0000-0001-7424-5957
University of Almería · ESCycloLab (Hungary) · HUSemmelweis University · HU

Funding

Emberi Eroforrások Minisztériuma (Ministry of Human Capacities) ÚNKP-19-4-SE-53Ministerio de Economía y Competitividad (Ministry of Economy and Competitiveness) CTQ2017-90050-R
6 · The paper itself

Abstract

Per(6-O-tert-butyldimethylsilyl)-α-, β- and γ-cyclodextrin derivatives are well-known as synthetic intermediates that enable the selective mono-, partial, or perfunctionalization of the secondary face of the macrocycles. Although silylation of the primary rim is readily achieved by treatment with tert-butyldimethylsilyl chloride in the presence of pyridine (either alone or mixed with a co-solvent), the reaction typically results in a mixture containing both under- and oversilylated byproducts that are difficult to remove. To address this challenge in preparing a pure product in high yield, we describe an approach that centers on the addition of a controlled excess of silylating agent to avoid the presence of undersilylated species, followed by the removal of oversilylated species by column chromatography elution with carefully designed solvent mixtures. This methodology works well for 6-, 7-, and 8-member rings (α-, β-, and γ-cyclodextrins, respectively) and has enabled us to repeatedly prepare up to ⁓35 g of ≥98% pure product (as determined by HPLC) in 3 d. We also provide procedures for lower-scale reactions, as well as an example of how the β-cyclodextrin derivative can be used for functionalization of the secondary face of the molecule.

Indexed as

beta-CyclodextrinsCyclodextrinsgamma-CyclodextrinsMolecular StructureOrganosilicon CompoundsSiliconStereoisomerismbeta-CyclodextrinsbetadexCyclodextrinsgamma-CyclodextrinsOrganosilicon CompoundsSilicontert-butyldimethylsilyl chloride

Identifiers

PMID33452503
OpenAlexW3122110992

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.